| Metric | Current Period | Same Period of Previous Year | YoY |
|---|---|---|---|
| Revenue | ¥2404.0B | ¥2065.1B | +16.4% |
| Operating Income | ¥289.5B | ¥166.0B | +74.4% |
| Profit Before Tax | ¥275.6B | ¥168.9B | +63.2% |
| Net Income | ¥191.0B | ¥89.9B | +112.5% |
| ROE | 2.6% | 1.1% | - |
The current period posted increases in both revenue and earnings, demonstrating a favorable earnings structure in which operating income growth significantly outpaced revenue growth. Revenue was ¥2404.0B (+16.4% YoY), operating income was ¥289.5B (+74.4%), profit before tax was ¥275.6B (+63.2%), and net income was ¥191.0B (+112.5%). The primary drivers of earnings growth were the strong growth of the core Gastrointestinal Endoscopy Solutions business and the emergence of operating leverage, as SG&A growth was contained relative to the increase in revenue.
【Revenue】Revenue increased 16.4% YoY to ¥2404.0B. Gastrointestinal Endoscopy Solutions led overall growth with revenue of ¥1684.5B (+21.2%), accounting for 70.1% of total revenue. Surgical and Interventional Solutions grew more moderately, with revenue of ¥719.2B (+6.7%).
【Profit and Loss】Operating income increased 74.4% to ¥289.5B, and the operating margin improved to 12.0% from 8.0% in the same period of the previous year, an improvement of +397bp. The gross margin remained high at 65.2%, while SG&A expenses increased only 2.3% against a ¥125.0B increase in revenue, contributing to operating leverage and margin improvement. Equity-method losses deteriorated to -¥11.2B from a gain of +¥2.5B in the previous year and exerted downward pressure on profit before tax. Nevertheless, profit before tax increased 63.2% to ¥275.6B, while net income increased 112.5% to ¥191.0B, with the net income growth rate exceeding that of operating income. The increase in net income was driven by a decline in the effective tax rate from 46.7% in the previous year to 30.7%. Overall, the Company recorded increases in both revenue and earnings, with earnings growth significantly exceeding revenue growth.
Profitability disparities between segments have widened. Gastrointestinal Endoscopy Solutions achieved both high profitability and high growth, with revenue of ¥1684.5B (+21.2%), operating income of ¥386.5B (+113.0%), and a margin of 22.9%, accounting for the majority of total operating income (unadjusted segment total of ¥362.4B). In contrast, Surgical and Interventional Solutions recorded revenue of ¥719.2B (+6.7%) and an operating loss of ¥24.0B, deteriorating from a loss of -¥18.6B in the previous year. Its margin widened to a loss of -3.3%, making it a factor diluting the Company-wide margin. The -¥72.9B adjustment between total operating income of ¥289.5B and the segment total of ¥362.4B represented a reversal from the +¥3.1B adjustment in the same period of the previous year, which included a one-time consideration related to a subsidiary of ¥5,995 million. In the current period, the burden of corporate expenses was relatively heavier.
【Profitability】The operating margin of 12.0% and net margin of 7.9% both improved from the previous year (8.0% and 4.4%, respectively), while the gross margin remained high at 65.2%. 【Cash Quality】Operating Cash Flow (OCF) was ¥143.3B, only 0.75 times net income of ¥191.0B. An increase in inventories of ¥123.4B and a decrease in accounts payable of ¥177.9B placed pressure on working capital, while income taxes paid of ¥136.2B were also incurred ahead of earnings realization. 【Investment Efficiency】ROE was 2.6%. Although this appears low because it is based on a simple comparison without annualizing quarterly earnings, the assessment of asset efficiency will be affected by the realization of future integration benefits from investment CF of -¥642.5B, including ¥431.7B for the acquisition of subsidiaries. 【Financial Soundness】The equity ratio declined to 49.0% from 52.8% at the end of the previous fiscal year. Current bonds and borrowings increased to ¥1391.3B, while cash and cash equivalents declined to ¥1185.5B.
OCF was ¥143.3B, improving from -¥152.0B in the same period of the previous year, but remained below net income of ¥191.0B. The ¥123.4B increase in inventories and ¥177.9B decrease in accounts payable were sources of working capital pressure. Investing CF recorded a substantial outflow of -¥642.5B, primarily due to ¥431.7B in expenditures for the acquisition of subsidiaries and ¥162.5B in capital expenditures. Financing CF was -¥209.8B. Shareholder returns consisting of dividend payments of ¥330.3B and share repurchases of ¥600.0B were partially funded by a ¥579.5B increase in short-term borrowings. As a result, free cash flow (OCF + investing CF) was -¥499.1B, and cash at the end of the period declined by ¥694.9B to ¥1185.5B. The fact that investment and shareholder-return activities exceeded internally generated cash and significantly reduced cash on hand warrants attention in assessing funding trends.
The core source of earnings was operating income from the main business, while the scale of non-operating items was limited. In addition to financial income of ¥14.3B, financial expenses of ¥28.2B, and equity-method losses of -¥11.2B, which deteriorated from a gain of +¥2.5B in the previous year, other income of ¥10.8B and other expenses of ¥28.0B were recorded, resulting in profit before tax of ¥275.6B. As a one-time item, an impairment loss of ¥0.27B was recorded, although its scale was immaterial. Meanwhile, the fact that OCF was below net income (0.75 times) was attributable to working capital changes, including the increase in inventories and decrease in accounts payable, indicating that the improvement in income statement earnings did not fully translate into an increase in cash. Comprehensive income was ¥280.5B, exceeding net income of ¥191.0B. The primary factor behind the difference was foreign currency translation adjustments for foreign operations of ¥111.6B, indicating that exchange-rate factors unrelated to the Company’s underlying operating earnings contributed to the increase in comprehensive income.
The full-year dividend forecast is ¥30.00 per share, and neither the earnings forecast nor the dividend forecast was revised during the current quarter. Dividend payments during the current period totaled ¥330.3B, while share repurchases of ¥600.0B were also conducted, bringing total shareholder returns, including dividends and share repurchases, to ¥930.3B. Against net income of ¥191.0B, the Total Return Ratio was approximately 487%, a high level. With free cash flow at -¥499.1B, shareholder returns exceeding internally generated cash were funded through increased borrowings and the utilization of cash on hand. As calculating the Payout Ratio based solely on quarterly results is susceptible to timing differences, it is useful to verify it together with full-year results.
Concentration of segment profitability: Surgical and Interventional Solutions recorded an operating loss of ¥24.0B, with its margin deteriorating to -3.3%, while losses widened from the previous year. Company-wide earnings are highly dependent on Gastrointestinal Endoscopy Solutions, which has a margin of 22.9%.
Weak cash conversion: OCF of ¥143.3B was only 0.75 times net income of ¥191.0B. This was attributable to working capital changes, including an increase in inventories of +¥123.4B and a decrease in accounts payable of -¥177.9B.
Increase in goodwill and burden of shareholder returns: Goodwill increased from ¥1942.4B at the end of the previous fiscal year to ¥2401.3B (+23.6%) due to the ¥431.7B acquisition of subsidiaries. Meanwhile, shareholder returns totaling ¥930.3B, consisting of dividends of ¥330.3B and share repurchases of ¥600.0B, significantly exceeded OCF for the current period, and total equity declined to ¥7479.0B (-7.9% versus the end of the previous fiscal year).
Profitability and Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | 12.0% | 8.7% (4.2%–14.2%) | +3.3pt |
| Net Margin | 7.9% | 7.0% (3.2%–10.6%) | +0.9pt |
The Company’s operating margin and net margin both exceed the industry median, placing its profitability at a high level within the industry.
Growth and Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (YoY) | 16.4% | 6.2% (-1.1%–14.6%) | +10.1pt |
The revenue growth rate exceeds the industry’s upper range, indicating a high pace of growth relative to peers.
※Source: Compiled by the Company
The operating margin improved by +397bp from the previous year to 12.0%. Operating leverage emerged as the Company maintained a gross margin of 65.2% while keeping SG&A growth below revenue growth.
Profitability disparities between segments are significant. Gastrointestinal Endoscopy Solutions, with a margin of 22.9%, supports Company-wide earnings, while losses in Surgical and Interventional Solutions have widened.
While OCF was below net income (0.75 times), cash declined by ¥694.9B due to investment and shareholder-return activities, including the acquisition of subsidiaries and share repurchases. The trajectory of cash flow will therefore remain an important area of focus.
This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly available earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting with a professional as necessary.
---End of Report---
These are mechanically computed values based on a residual income model. They are not a forecast of market prices or a recommendation of any investment action, and do not predict or guarantee future share prices. Historical values are computed retrospectively using current guidance-achievement statistics.